ELI LILLY & Co
Close on Nov 2, 2026Market cap $1.33TP/E 45.8Yield 0.44%
Eli Lilly Baqsimi (nasal glucagon) by Quarter
Baqsimi (nasal glucagon) — Worldwide revenue ($M) [legacy separate disclosure] ($M)
Eli Lilly Baqsimi (nasal glucagon): $4.30M in Q4 2024, down 77.6% from a year earlier. That is the lowest of the 12 quarters on record here. No newer figure appears in the documents we track.
Where the Q4 2024 figure comes from
Calculated from reported figures: Q4 = full year (10-K) − nine months (10-Q)
Source: Form 10-K FY2024 (filed 2025-02-19) ↗
Reported in Form 10-Q / 10-K Note 2 & MD&A (legacy separate product disclosure prior to FY2025 reorganization).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Baqsimi (nasal glucagon) — Worldwide revenue ($M) [legacy separate disclosure] ($M) | Year on year | Source |
|---|---|---|---|---|
| Q4 2024 | Dec 31, 2024 | 4.30 | -77.6% | Form 10-K FY2024 (filed 2025-02-19) ↗ |
| Q3 2024 | Sep 30, 2024 | 13.4 | +2.3% | Form 10-Q (filed 2024-10-30) ↗ |
| Q2 2024 | Jun 30, 2024 | 12.4 | -98.0% | Form 10-Q (filed 2024-08-08) ↗ |
| Q4 2023 | Dec 31, 2023 | 19.2 | -49.6% | Form 10-K FY2023 (filed 2024-02-21) ↗ |
| Q3 2023 | Sep 30, 2023 | 13.1 | -69.5% | Form 10-Q (filed 2024-10-30) ↗ |
| Q2 2023 | Jun 30, 2023 | 614 | +2,016.9% | Form 10-Q (filed 2024-08-08) ↗ |
| Q4 2022 | Dec 31, 2022 | 38.1 | – | Form 10-K FY2023 (filed 2024-02-21) ↗ |
| Q3 2022 | Sep 30, 2022 | 43 | – | Form 10-Q (filed 2023-11-02) ↗ |
| Q2 2022 | Jun 30, 2022 | 29 | – | Form 10-Q (filed 2023-08-08) ↗ |
| Q4 2020 | Dec 31, 2020 | 23.8 | +47.8% | Earnings Release (Form 8-K FY2020Q4 EX-99.1) (filed 2021-01-29) ↗ |
| Q1 2020 | Mar 31, 2020 | 17.8 | – | Earnings Release (Form 8-K FY2020Q1 EX-99.1) (filed 2020-04-23) ↗ |
| Q4 2019 | Dec 31, 2019 | 16.1 | – | Earnings Release (Form 8-K FY2020Q4 EX-99.1) (filed 2021-01-29) ↗ |
Breakdown
What makes up baqsimi (nasal glucagon)
Cite this data
StockData. (2026). Eli Lilly Baqsimi (nasal glucagon) ($M), quarterly Q4 2019–Q4 2024 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med-baqsimi-ww
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.